Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: What does current evidence tell us?

Sabino De Placido, Paolo Pronzato

Research output: Contribution to journalArticle

Abstract

Many postmenopausal women with advanced or metastatic breast cancer (BC) receive nonsteroidal aromatase inhibitors (NSAIs). Virtually all of them experience progression, but may still gain benefit from a different endocrine or targeted agent. We indirectly compare the results of trials on endocrine or targeted treatment in HR+/HER2- mBC patients who progressed after a prior NSAI therapy. Although with the limitations of any indirect comparison, evidence suggests that only the combination of everolimus and exemestane is associated with a prolonged progression-free survival and a more evident clinical benefit than its comparators. We speculate that prior NSAI therapy can 'per se' individuate patients eligible to everolimus. More robust data from head-to-head trials will provide more grounded evidence on this issue.

Original languageEnglish
Pages (from-to)975-981
Number of pages7
JournalFuture Oncology
Volume11
Issue number6
DOIs
Publication statusPublished - Mar 1 2015

    Fingerprint

Keywords

  • aromatase inhibitors
  • breast cancer
  • disease progression
  • endocrine treatment
  • second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this